시장보고서

상품코드

1726373

세계의 갑상선암 진단 시장 : 시장 규모, 점유율, 동향 분석 - 암 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy, Blood Test), By End-use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 04월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

갑상선암 진단 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 갑상선암 진단 시장은 2030년까지 41억 3,000만 달러에 달할 것으로 예측되고, 예측 기간 CAGR 5.3%로 확대될 것으로 예측되고 있습니다.

이 시장의 성장은 질병 유병률 증가와 신규 진단 제품의 출현에 기인하고 있습니다. 암은 세계적으로 드문 질환이지만, 이환율은 증가하는 추세이며, 이 질환을 진단하는 도구의 감도와 정확도가 향상되고 있는 것이 그 요인이 되고 있습니다. 갑상선암은 갑상선의 비정상적인 세포 분열의 결과로 개발됩니다. 갑상선 호르몬은 체중, 체온, 심박수, 혈압 등 여러 기능을 조절하고 있기 때문에 구조적 또는 기능적 이상은 앞서 언급한 인자 중 몇 가지 또는 모두에 영향을 미칠 가능성이 높습니다.

의식 증가와 공중 보건 이니셔티브는 더 많은 개인, 특히 위험이 높은 사람들이 검진을 받도록 촉구하고 있습니다. 이는 의료 인프라의 확대나 세계의 의료비 증가와 맞물려 고도의 진단 서비스에 대한 접근을 촉진합니다. 규제 당국의 지원과 지속적인 연구 노력으로 리퀴드바이옵시와 인공지능을 활용한 영상 분석 등 혁신적인 진단 솔루션 도입이 촉진되고 있습니다.

시장은 지난 몇 년 동안 바이오마커의 도입과 개선된 진단제의 출시를 통해 패러다임 전환을 이루고 있습니다. 그러나 질환의 진행과 재발은 특히 고령 환자에서 여전히 높은 수준에 있습니다. 강력한 암메트니즈는 획기적인 퍼스트 인 클래스 진단약을 개발할 중요한 기회가 되고 있습니다.

갑상선암 진단 시장 보고서, 하이라이트

유두암은 2024년 매출액 점유율 80.0%로 암종 부문을 리드했습니다. 이것은 일반 시민의 의식 고조, 검진 이니셔티브 확대, 화상 진단 및 분자 진단법의 대폭적인 진보에 의한 것으로, 이들 모두가 보다 조기에, 보다 높은 정확도로 증례를 특정하는 것을 가능하게 했습니다.
여포암 진단은 여성의 취약성 증가, 신속 진단 중시, 진단 기술의 지속적인 진보로 예측 기간 중 CAGR 5.6%를 보일 것으로 예측됩니다.
영상 진단 기술은 2024년에 36.9%의 최대 판매 점유율을 차지했으며, 종양의 정확한 위치 확인과 모니터링을 위한 영상 해상도 향상 및 인공지능의 통합이 견인하고 있습니다.
생검 기술은 바이오마커 분석과 차세대 시퀀싱의 진보에 의해 진단 정밀도가 향상되어 맞춤형 치료가 가능해졌기 때문에 예측 기간 중에 높은 CAGR을 나타낼 전망입니다.
2024년에는 병원 검사실이 최대의 매출 점유율을 차지했습니다. 연구기관은 2025-2030년 CAGR 6.4%로 성장할 전망입니다.
북미는 2024년에 세계의 갑상선암 진단 시장에서 가장 큰 매출 점유율을 차지했으며, 그 주요 요인은 고급 의료 인프라의 존재, 지속적인 계발 캠페인, 혁신적인 진단 솔루션에 대한 액세스입니다.

시장 대시보드 : 지역별
시장 점유율 분석 : 지역별(2024년, 2030년)
갑상선암 진단 시장 : 지역별 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

최근 동향과 영향 분석 : 주요 시장 진출 기업별
기업 및 경쟁의 분류
벤더 상황
- 주요 기업의 히트맵 분석(2024년)
기업 프로파일
- Abbott
- F.Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc.
- GE HealthCare
- Hologic, Inc.
- Koninklijke Philips NV
- Toshiba Corporation
- Agilent Technologies, Inc.
- Illumina, Inc.

AJY 25.05.29

Thyroid Cancer Diagnostics Market Growth & Trends:

The global thyroid cancer diagnostics market is anticipated to reach USD 4.13 billion by 2030 and is anticipated to expand at a CAGR of 5.3% over the forecast period, according to a new report by Grand View Research, Inc. The growth of the market is attributed to increasing disease prevalence and the emergence of novel diagnostic products. Although cancer is uncommon worldwide, the incidence rate is on the rise-driven by more sensitive and precise tools to diagnose the disease. It develops as a result of abnormal cell division in the thyroid gland. Since the glandular hormones regulate several functions, such as weight, body temperature, heart rate, and blood pressure, structural or functional anomalies are likely to affect several or all of the aforementioned factors.

Growing awareness and public health initiatives encourage more individuals, especially those at higher risk, to seek screening. This, combined with expanding healthcare infrastructure and increased healthcare spending worldwide, facilitates greater access to advanced diagnostic services. Regulatory support and ongoing research efforts are fostering the introduction of innovative diagnostic solutions, including liquid biopsies and artificial intelligence-driven imaging analysis.

The market has undergone a paradigm shift over the last few years, driven by the introduction of biomarkers and the launch of improved diagnostic products. However, disease progression and recurrence remain high, especially among older patients. Strong unmet needs present a key opportunity to develop breakthrough, first-in-class diagnostics of the disease.

Thyroid Cancer Diagnostics Market Report Highlights:

Papillary carcinoma led the cancer type segment with the largest revenue share of 80.0% in 2024. This is attributed to heightened public awareness, the expansion of screening initiatives, and significant progress in imaging and molecular diagnostic methods, all of which have made it possible to identify cases earlier and with greater accuracy.
Follicular carcinoma diagnostics is expected to grow at a CAGR of 5.6% over the forecast period, owing to an increased vulnerability among women, a stronger emphasis on prompt diagnosis, and ongoing advancements in diagnostic technologies.
Imaging technique held the largest revenue share, 36.9%, in 2024, driven by the incorporation of enhanced imaging resolution and artificial intelligence for precise tumor localization and monitoring.
Biopsy technique is expected to grow at a significant CAGR over the forecast period, owing to advances in biomarker analysis and next-generation sequencing, which have improved diagnostic accuracy and supported individualized care.
Hospital laboratories accounted for the largest revenue share in 2024. Research institutes are expected to grow at a CAGR of 6.4% from 2025 to 2030.
North America dominated the global thyroid cancer diagnostics market with the largest revenue share in 2024, primarily driven by the presence of advanced healthcare infrastructure, ongoing awareness campaigns, and access to innovative diagnostic solutions.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Cancer Type
- 1.2.2. Technique
- 1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Cancer Type Outlook
- 2.2.2. Technique Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
2.3. Competitive Insights

Chapter 3. Global Thyroid Cancer Diagnostics Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Global Thyroid Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. Global Thyroid Cancer Diagnostics Market: Cancer Type Business Analysis

4.1. Cancer Type Segment Dashboard
4.2. Thyroid Cancer Diagnostics Market: Cancer Type Movement Analysis
4.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer Type, 2018 to 2030 (USD Million)
4.4. Papillary carcinoma
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Follicular carcinoma
- 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Others
- 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Thyroid Cancer Diagnostics Market: Technique Business Analysis

5.1. Technique Segment Dashboard
5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
5.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2018 to 2030 (USD Million)
5.4. Blood Test
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Imaging
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Biopsy
- 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Others
- 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Thyroid Cancer Diagnostics Market: End Use Business Analysis

6.1. End Use Segment Dashboard
6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
6.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
6.4. Hospital Laboratories
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Cancer Diagnostic Centers
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Research Institutes
- 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Others
- 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Thyroid Cancer Diagnostics Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Global Thyroid Cancer Diagnostics Market by Regional: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key Country Dynamics
  - 7.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.1.3. Competitive Scenario
  - 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. Germany
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.1.3. Competitive Scenario
  - 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.4.3. Competitive Scenario
  - 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.5.3. Competitive Scenario
  - 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.6. Denmark
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.6.3. Competitive Scenario
  - 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.7.3. Competitive Scenario
  - 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.8. Norway
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.8.3. Competitive Scenario
  - 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.1.3. Competitive Scenario
  - 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.5. Thailand
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.6.3. Competitive Scenario
  - 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key Country Dynamics
  - 7.7.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.1.3. Competitive Scenario
  - 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.2.3. Competitive Scenario
  - 7.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8. Middle East & Africa
- 7.8.1. South Africa
  - 7.8.1.1. Key Country Dynamics
  - 7.8.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.1.3. Competitive Scenario
  - 7.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.2.3. Competitive Scenario
  - 7.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.3.3. Competitive Scenario
  - 7.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.4.3. Competitive Scenario
  - 7.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
- 8.4.1. Abbott
  - 8.4.1.1. Company Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. F.Hoffmann-La Roche Ltd.
  - 8.4.2.1. Company Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Thermo Fisher Scientific, Inc.
  - 8.4.3.1. Company Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Siemens Healthcare GmbH
  - 8.4.4.1. Company Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. Bio-Rad Laboratories, Inc.
  - 8.4.5.1. Company Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. GE HealthCare
  - 8.4.6.1. Company Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Hologic, Inc.
  - 8.4.7.1. Company Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Koninklijke Philips N.V.
  - 8.4.8.1. Company Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Toshiba Corporation
  - 8.4.9.1. Company Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Agilent Technologies, Inc.
  - 8.4.10.1. Company Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives
- 8.4.11. Illumina, Inc.
  - 8.4.11.1. Company Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Strategic Initiatives

세계의 갑상선암 진단 시장 : 시장 규모, 점유율, 동향 분석 - 암 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy, Blood Test), By End-use, By Region, And Segment Forecasts, 2025 - 2030

갑상선암 진단 시장의 성장 및 동향 :

갑상선암 진단 시장 보고서, 하이라이트

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 갑상선암 진단 시장 : 변동 요인, 경향 및 범위

제4장 세계의 갑상선암 진단 시장 : 암 유형별 비즈니스 분석

제5장 세계의 갑상선암 진단 시장 : 기술별 비즈니스 분석

제6장 세계의 갑상선암 진단 시장 : 최종 용도별 비즈니스 분석

제7장 세계의 갑상선암 진단 시장 : 지역별 추정 및 동향 분석